Parathyroid Tumor Clonal Status

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Aug 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying parathyroid tumors in women who have been diagnosed with primary hyperparathyroidism (PHPT), a condition where the parathyroid glands produce too much hormone, leading to high levels of calcium in the blood. The researchers want to understand how often these tumors are made up of one type of cell (monoclonal) versus multiple types of cells (polyclonal) and how this relates to conditions where multiple glands are affected. To do this, they will compare the results of surgeries on patients having their parathyroid glands removed.

To be eligible for this trial, participants must be women aged 18 or older who have been diagnosed with nonfamilial primary hyperparathyroidism confirmed by blood tests. Importantly, patients who have had radiation treatment in the neck, those with recurring issues after previous surgeries, or those with certain types of kidney-related parathyroidism are not eligible. Participants can expect to undergo a thorough evaluation, including surgery, and their outcomes will help improve understanding of parathyroid tumors and their treatment. This research is currently looking for willing volunteers to join.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with nonfamilial primary hyperparathyroidism biochemically confirmed by measurement of serum calcium and intact PTH within 60 days of enrollment.
• • Female.
• • Age ≥ 18 years
• • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
• Exclusion Criteria:
• • Patients with a history of cervicofacial irradiation.
• • Patients with recurrent or persistent PHPT after prior PTX.
• • Patients with secondary hyperparathyroidism due to renal failure on renal replacement therapy (i.e. hemodialysis or peritoneal dialysis).
• • Patients with tertiary hyperparathyroidism due to renal failure with or without history of renal transplantation.
• • Patients receiving calcimimetic agents (e.g. cinacalcet / Sensipar) within 30 days of PTX.
• • Patients currently taking lithium or with a history of lithium use.
• • Pregnant patients